MONROVIA, CA, March 19, 2009
/24-7PressRelease/ -- Pete Adamson, Head of Research for Ophthiris at GlaxoSmithKline (GSK) will give the Keynote Presentation at GTCbio's Inaugural Ocular Diseases & Drug Discovery conference, taking place on April 20-21, 2009 in Philadelphia, Pennsylvania.
In 2005, the National Eye Institute (NEI) estimated that the annual cost of vision impairment and eye disease to the United States was $68 billion. Not only are eye diseases costly to the US, they also impact the quality of life of over 34 million people, causing lost productivity, reduced independence, diminished quality of life, increased depression and accelerated mortality. By 2020, this number is expected to grow to over 50 million.
Pete Adamson is leading the charge in fighting Ocular diseases and the devastating statistics that come with it. Pete first joined GSK in 2004 as Head of Cellular Pharmacology within the Atherosclerosis group, part of the Cardiovascular and Urogenital CEDD before working with the GSK Centre of Excellence in External Drug Discovery (CEEDD) where he was responsible for inflammation and ophthalmology opportunities. During his time in the CEEDD Pete was involved in the selection of programs and targets for the ChemoCentryx, Pharmacopeia, Praecis, and Ranbaxy strategic alliances many of which are now under clinical investigation.
Pete briefly joined Ophthaltec Limited as CEO before taking up his appointment with Ophthiris in 2008. Pete obtained his PhD in Biochemistry from the University of London (Institute of Psychiatry) and subsequently worked as a postdoctoral researcher at the Institute of Cancer Research and Vascular Biology Research Centre before taking up an academic position at the UCL Institute of Ophthalmology from 1994-2004 where he was a principle investigator and Reader in Molecular Pathology.
For more information on attending, presenting a poster, or sponsoring, please visit http://gtcbio.com/conferenceDetails.aspx?id=148
About GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
---
Press release service and press release distribution provided by http://www.24-7pressrelease.com# # #
Read more Press Releases from Rania Hafez:- Joost Oppenheim, M.D., Laboratory Chief - NCI, to give Keynote Presentation at GTCbio's 8th Cytokines & Inflammation Conference on January 28-29, 2010 in San Diego, CA
- Vaccines: All Things Considered Conference to be held by GTCbio on November 9-10, 2009 in Washington, DC
- Translational Medicine Track of the GTCbio 5th Annual Modern Drug Discovery & Development Conference to be held on October 14-16, 2009 in San Diego, CA
- Amy Scott-Billman, VP at GlaxoSmithKline to do Keynote at Modern Drug Discovery & Development Summit
- Biological Therapeutics to be an Important Focus at the 5th Modern Drug Discovery & Development Summit held by GTCbio on October 14-16, 2009 in San Diego, CA.
- GTCbio Announces 4th Annual Assay Development and Screening Conference taking place June 8-9, 2009.
- Dr. Joseph Bolen, CSO of Millennium to give Keynote Presentation at GTCbio's 4th Annual Protein Kinases in Drug Discovery Conference taking place on May 4-5, 2009 in Boston, MA
- GTCbio Announces its Inaugural Ocular Diseases & Drug Discovery conference, taking place on April 20-21, 2009 in Philadelphia, Pennsylvania.
- Alison Goss Eng of US Dept. of Energy to Present at GTCbio's Inaugural Biofuels: Science and Innovation for Sustainable Development Conference on June 29-30, 2009 in San Francisco, CA
- GTCbio Announces its Inaugural Ocular Diseases & Drug Discovery conference, taking place on April 20-21, 2009 in Philadelphia, Pennsylvania.
